AXIM Biotechnologies, Inc. (AXIM) stock
Close on Oct 19, 2026Market cap –P/E –Yield –
AXIM Biotechnologies, Inc. grew revenue 254.6% to $92.90K over the twelve months to Jun 30, 2024. Free cash flow was -$1.03M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2024
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $92.90K
- Net income
- -$4.14M
- EPS, diluted
- -$0.04
- Free cash flow
- -$1.03M
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 196,278
- Average volume (20 days)
- 148,460
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | AXIM | S&P 500 | Difference | AXIM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.5% | +0.6% | −24.1 pts | ||
| 3 months | -17.1% | +3.4% | −20.5 pts | ||
| Year to date | -71.4% | +13.3% | −84.7 pts | ||
| 1 year | -57.5% | +16.6% | −74.1 pts | ||
| 3 years | -83.9% | +86.4% | −170.3 pts | -45.6% | +23.1% |
| 5 years | -99.3% | +81.9% | −181.2 pts | -63.2% | +12.7% |
| 10 years | -99.1% | +318.9% | −418.0 pts | -37.7% | +15.4% |
Fourteen years at a glance
Fiscal years 2010 to 2023 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases AXIM Biotechnologies filed with the SEC as exhibits to Form 8-K or 6-K
About AXIM Biotechnologies
Pharmaceutical Preparations
Axim Biotechnologies, Inc. develops point-of-care diagnostic healthcare solutions focused on rapid lateral flow immunoassays. The company operates primarily in eye health diagnostics, offering FDA-cleared tear tests for dry eye disease biomarkers, including Lactoferrin and Immunoglobulin E, paired with portable digital readers. Axim also maintains diagnostic assays developed for SARS-CoV-2 neutralizing antibodies and works on additional tests for biomarkers such as MMP-9. The company provides its diagnostic systems to ophthalmologists and optometrists to assist clinicians and eye care technicians in identifying and treating ocular surface conditions.
Company profile, executives and historyAXIM Biotechnologies stock: common questions
What is AXIM Biotechnologies's stock price?
AXIM closed at $0.00 on Oct 19, 2026, up 2.00% on the day.
What is AXIM's P/E ratio?
AXIM Biotechnologies lost money over fiscal 2023 (diluted EPS -$0.04), so it has no meaningful P/E ratio.
How much revenue does AXIM Biotechnologies make?
AXIM Biotechnologies reported revenue of $92.90K for the twelve months to Jun 30, 2024, up 254.6% from a year earlier.
Does AXIM Biotechnologies pay a dividend?
No. AXIM Biotechnologies has not paid a cash dividend over the last twelve months.
How has AXIM stock performed over the past year?
Including dividends, AXIM returned -57.5% over the past year, against +16.6% for the S&P 500.
Who are AXIM Biotechnologies's competitors?
Companies most similar to AXIM Biotechnologies by business, industry and size include ALDX, REGN, HROW, OCUL, ONCO.
See a number that looks wrong?